Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential irinotecan-based versus continuous irinotecan-based chemotherapy for metastatic colorectal cancer
ACTRN12609000585224Phase 2Completed
- Sponsor
- HeCOG
- Start
- Nov 2001
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil, folinic acid and oxaliplatin in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by HeCOG. Primary endpoint: Objective response rate. Started Nov 2001; status: completed.
02
Drugs
irinotecanfluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ACTRN12609000585224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000585224.